Related Experiment Video
Updated: Jul 11, 2025

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
Published on: March 2, 2014
Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during
Juliana Bragazzi Cunha1, Kyle Leix1, Emily J Sherman1
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract:
Disease progression during SARS-CoV-2 infection is tightly linked to the fate of lung epithelial cells, with severe cases of COVID-19 characterized by direct injury of the alveolar epithelium and an impairment in its regeneration from progenitor cells. The molecular pathways that govern respiratory epithelial cell death and proliferation during SARS-CoV-2 infection, however, remain unclear. We now report a high-throughput CRISPR screen for host genetic modifiers of the survival and proliferation of SARS-CoV-2-infected Calu-3 respiratory epithelial cells. The top four genes identified in our screen encode components of the same type I interferon (IFN-I) signaling complex—IFNAR1, IFNAR2, JAK1, and TYK2. The fifth gene, ACE2, was an expected control encoding the SARS-CoV-2 viral receptor. Surprisingly, despite the antiviral properties of IFN-I signaling, its disruption in our screen was associated with an increase in Calu-3 cell fitness. We validated this effect and found that IFN-I signaling did not sensitize SARS-CoV-2-infected cultures to cell death but rather inhibited the proliferation of surviving cells after the early peak of viral replication and cytopathic effect. We also found that IFN-I signaling alone, in the absence of viral infection, was sufficient to induce this delayed antiproliferative response in both Calu-3 cells and iPSC-derived type 2 alveolar epithelial cells. Together, these findings highlight a cell autonomous antiproliferative response by respiratory epithelial cells to persistent IFN-I signaling during SARS-CoV-2 infection. This response may contribute to the deficient alveolar regeneration that has been associated with COVID-19 lung injury and represents a promising area for host-targeted therapeutic development.
Insights
Type I interferon (IFN-I) signaling impairs lung epithelial cell proliferation after SARS-CoV-2 infection, hindering COVID-19 lung repair. Disrupting this pathway may improve alveolar regeneration and offers a therapeutic target.
Area of Science:
- Molecular biology
- Virology
- Cell biology
Background:
- COVID-19 severity correlates with lung epithelial cell damage and impaired regeneration.
- Molecular mechanisms governing epithelial cell death and proliferation during SARS-CoV-2 infection are not fully understood.
- Alveolar epithelial progenitor cell dysfunction contributes to COVID-19 lung injury.
Purpose of the Study:
- To identify host genetic factors influencing the survival and proliferation of SARS-CoV-2-infected lung epithelial cells.
- To elucidate the role of type I interferon (IFN-I) signaling in the cellular response to SARS-CoV-2 infection.
- To explore potential host-targeted therapeutic strategies for improving COVID-19 lung regeneration.
Main Methods:
- High-throughput CRISPR screening of host genes in SARS-CoV-2-infected Calu-3 respiratory epithelial cells.
- Validation of top genetic hits using cell culture models.
- Assessment of cell proliferation and death in response to IFN-I signaling, with and without viral infection.
Main Results:
- CRISPR screen identified components of the type I interferon (IFN-I) signaling pathway (IFNAR1, IFNAR2, JAK1, TYK2) as key regulators.
- Disruption of IFN-I signaling increased the fitness of infected Calu-3 cells.
- IFN-I signaling inhibited proliferation of surviving lung epithelial cells post-infection and also in uninfected cells, suggesting a delayed antiproliferative effect.
Conclusions:
- Persistent IFN-I signaling triggers a cell-autonomous antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.
- This IFN-I-mediated inhibition of proliferation may impair alveolar regeneration in COVID-19.
- Targeting the IFN-I pathway presents a potential therapeutic avenue for enhancing lung repair in COVID-19 patients.
More Related Videos
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013